Inhibition of leucine-rich kinase 2 (LRRK2) promotes peripheral axon regeneration via phosphorylation-network
Eun-Hae Jang1,2,3, Eun Mo Yang1,4, Gil Song1,4
1Laboratory of Neuroscience, College of Veterinary Medicine, Seoul National University, Seoul, Republic of Korea.
Background And Purpose:
In contrast to neurons in the central nervous system, neurons in the peripheral nervous system can regenerate axons after injury via activation of a pro-regenerative transcriptional programme. Pathogenic mutations in leucine-rich repeat kinase 2 (LRRK2) are the most common genetic cause of Parkinson's disease, and several small-molecule LRRK2 kinase inhibitors have been developed, with some in clinical trials. However, the physiological role of endogenous, non-pathogenic LRRK2 remains largely unknown.
Experimental Approach:
LRRK2 expression was examined in murine dorsal root ganglia (DRGs) following sciatic nerve crush (SNC) injury. Regenerative axon growth was assessed using cultured adult DRG neurons after genetic or pharmacological inhibition of LRRK2. Axon regeneration after SNC injury was evaluated in vivo following oral administration of the LRRK2 inhibitors, MLi-2 or PF-06447475. Axonal trafficking experiments and phosphoproteomic analyses were performed to investigate mechanisms underlying axon growth promotion induced by LRRK2 inhibitors.
Key Results:
SNC injury reduced LRRK2 expression in DRGs. Genetic and pharmacological inhibition of LRRK2 enhanced regenerative axon growth in culture. Oral administration of MLi-2 or PF-06447475 promoted axon regeneration in vivo after SNC injury. MLi-2 enhanced mitochondrial trafficking, and phosphoproteomic analyses identified cellular processes and kinase-substrate signalling networks associated with a pro-regenerative state triggered by LRRK2 inhibition.
Conclusion And Implications:
These findings identify endogenous, non-pathogenic LRRK2 as a suppressor of axon regeneration. They also support the potential repositioning of small-molecule LRRK2 inhibitors, including clinically advanced compounds and those in preclinical development, as therapeutic strategies to enhance peripheral nerve regeneration.
Insights
Leucine-rich repeat kinase 2 (LRRK2) normally suppresses peripheral nerve axon regeneration. Inhibiting LRRK2 promotes axon regrowth, suggesting LRRK2 inhibitors could treat nerve injuries.
Area of Science:
- Neuroscience
- Molecular Biology
Background:
- Peripheral nervous system (PNS) neurons regenerate axons after injury, unlike central nervous system neurons.
- Pathogenic mutations in leucine-rich repeat kinase 2 (LRRK2) are a common genetic cause of Parkinson's disease.
- The physiological role of endogenous, non-pathogenic LRRK2 in nerve regeneration is largely unknown.
Purpose of the Study:
- To investigate the role of endogenous LRRK2 in peripheral nerve axon regeneration.
- To determine if LRRK2 inhibition promotes axon regeneration after injury.
Main Methods:
- Examined LRRK2 expression in mouse dorsal root ganglia (DRGs) after sciatic nerve crush (SNC) injury.
- Assessed axon regeneration in cultured DRG neurons and in vivo after genetic or pharmacological LRRK2 inhibition.
- Utilized axonal trafficking and phosphoproteomic analyses to explore underlying mechanisms.
Main Results:
- SNC injury decreased LRRK2 expression in DRGs.
- Genetic and pharmacological LRRK2 inhibition enhanced axon regeneration in vitro and in vivo.
- LRRK2 inhibition promoted mitochondrial trafficking and identified pro-regenerative signaling pathways.
Conclusions:
- Endogenous LRRK2 acts as a suppressor of peripheral axon regeneration.
- Small-molecule LRRK2 inhibitors show potential for therapeutic strategies to enhance nerve regeneration.
Related Concept Videos
01:15Neurogenesis and Regeneration of Nervous Tissue
01:22PI3K/mTOR/AKT Signaling Pathway